Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial

Circulation: Cardiovascular Interventions

Volumn 5, Issue 5, 2012, Pages 633-640

  Ahn, Jung Min ^a   Park, Duk Woo ^a   Kim, Young Hak ^a   Song, Haegeun ^a   Cho, Young Rak ^a   Kim, Won Jang ^a   Lee, Jong Young ^a   Kang, Soo Jin ^a   Lee, Seung Whan ^a   Lee, Cheol Whan ^a   Park, Seong Wook ^a   Yun, Sung Cheol ^a   Han, Seungbong ^a   Lee, Sung Yun ^b   Lee, Bong Ki ^c   Cho, Jang Hyun ^d   Yang, Tae Hyun ^e   Lee, Nae Hee ^f   Yang, Joo Young ^g   Park, Jong Seon ^h   Shin, Won Yong ^f   Kim, Moo Hyun ⁱ   Bae, Jang Ho ^j   Kim, Myeong Kon ^k   Yoon, Junghan ^l   Park, Seung Jung ^a   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University   (South Korea)

^c Kangwon National University   (South Korea)

^d Saint Carollo Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Soonchunhyang University   (South Korea)

^g National Health Insurance Corporation   (South Korea)

^h Yeungnam University Hospital   (South Korea)

ⁱ Dong A Medical Center   (South Korea)

^j Konyang University College of Medicine   (South Korea)

^k Kyung Hee University College of Medicine   (South Korea)

^l Wonju Severance Christian Hospital   (South Korea)

more..

Author keywords

Angioplasty; Coronary disease; Stents

Indexed keywords

CYPHER SELECT PLUS; RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REPUBLIC OF KOREA; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868641244     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.965673     Document Type: Article

References (23)

1. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, De Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-Analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
2. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents. Circulation. 2006;113:2293-2300. (Pubitemid 43947975)
3. Suh J, Park DW, Lee JY, Jung IH, Lee SW, Kim YH, Lee CW, Cheong SS, Kim JJ, Park SW, Park SJ. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv. 2010;3:383-389.
4. Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, Wong J, Wilcox J. The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention. 2007;3:137-139.
5. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P. The next-generation Endeavor Resolute stent:4-month clinical and angiographic results from the Endeavor Resolute frst-in-man trial. EuroIntervention. 2007;3:50-53.
6. Serruys PW, Silber S, Garg S, Van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, Van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, Van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
7. Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, Ibrahim T, Fusaro M, Ott I, Schömig A, Laugwitz KL, Mehilli J; Intracoro-nary Stenting and Angiographic Results: Test Efficacy of Sirolimus-And Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators. Polymer-free sirolimus-And probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intra-coronary Stenting and Angiographic Results: Test Efficacy of Sirolimus-And Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation. 2011;124:624-632.
8. Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, McLaurin BT, Popma JJ, Fitzgerald PJ, Cutlip DE, Massaro JM, Mauri L; RESOLUTE US Investigators. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57:1778-1783.
9. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ; Long-DES-II Study Investigators. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006;114:2148-2153. (Pubitemid 44747895)
10. King SB, 3rd, Smith SC, Jr, Hirshfibro JW, Jr, Jacobs AK, Morrison DA, Williams DO, Fibroman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Hal-perin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW; 2005 WRITING COMMITTEE MEMBERS. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261-295.
11. Roy P, Steinberg DH, Sushinsky SJ, Okabe T, Pinto Slottow TL, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Weissman NJ, Lindsay J, Waksman R. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J. 2008;29:1851-1857.
12. Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, Kim YH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:1305-1310. (Pubitemid 43998103)
13. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJ. Comparison of zo-tarolimus-eluting stents with sirolimus-And paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol. 2010;56:1187-1195.
14. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-elut-ing stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation. 2007;115:2352-2357. (Pubitemid 46685904)
15. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Stone GW. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1193-1200. (Pubitemid 40523136)
16. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, Park DW, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Lee BK, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Park WJ, Kim HS, Chae JK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Choi YJ, Cheong SS, Yang TH, Jang JS, Her SH, Park SJ; ESSENCE-DIABETES Study Investigators. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation. 2011;124:886-892.
17. Mehran R, Mintz GS, Satler LF, Pichard AD, Kent KM, Bucher TA, Pop-ma JJ, Leon MB. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation. 1997;96:2183-2189.
18. Chow S-C, Liu J-P. Design and Analysis of Clinical Trials. 2nd ed. New York, NY: John Wiley and Son; 2004.
19. Romagnoli E, Godino C, Ielasi A, Gasparini G, Tzifos V, Sciahbasi A, Lioy E, Presbitero P, Colombo A, Sangiorgi G. Resolute Italian study in all comers: immediate and one-year outcomes. Catheter Cardiovasc Interv. 2012;79:567-574.
20. Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang Y, Lee MM, Koo BK, Oh DJ, Seung KB, Tahk SJ, Yoon J, Park SJ. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc Interv. 2006;67:181-187. (Pubitemid 43235148)
21. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee SW, Lee SW, Lee K, Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ. Comparison of evero-limus-And sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv. 2011;4:1096-1103.
22. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, De Paoli A, Negoita M, Fitzgerald PJ; RESOLUTE Investigators. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, frst-in-human trial. JACC Cardiovasc Interv. 2009;2:977-985.
23. Gutiérrez-Chico JL, Van Geuns RJ, Regar E, Van Der Giessen WJ, Kelbæk H, Saunamäki K, Escaned J, Gonzalo N, Di Mario C, Borgia F, Nüesch E, García-García HM, Silber S, Windecker S, Serruys PW. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fuoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J. 2011;32:2454-2463.